Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLEC | Q15149 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 10/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15485372 | 0.86 | RARA (0.41) | PLECCNR1CNR2TP53LMNA | |
| SCHEMBL5054252 | 0.86 | LMNA (0.50) | PLECCNR1TP53POLBALDH1A1 | |
| SCHEMBL13807942 | 0.85 | ALDH1A1 (0.43) | PLECCNR1CNR2TP53POLB | |
| SCHEMBL13807753 | 0.85 | LMNA (0.44) | PLECCNR1TP53POLBALDH1A1 | |
| SCHEMBL4670768 | 0.84 | PLEC (0.53) | PLECCNR1CNR2TP53POLB | |
| SCHEMBL14542555 | 0.84 | CNR1 (0.60) | PLECCNR1CNR2TP53POLB | |
| SCHEMBL5057385 | 0.84 | CNR1 (0.40) | PLECCNR1CNR2TP53POLB | |
| SCHEMBL14043713 | 0.83 | PLEC (0.52) | PLECCNR1CNR2TP53POLB | |
| SCHEMBL13807814 | 0.83 | PLEC (0.52) | PLECCNR1CNR2TP53POLB | |
| SCHEMBL5058714 | 0.82 | PLEC (0.39) | PLECCNR1CNR2TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009075691-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008118141-A2 | USE OF CANNABINOID MODULATING COMPOUNDS IN COMBINATION WITH OTHER THERAPEUTIC COMPOUNDS FOR ADJUNCTIVE THERAPY | ACADIA PHARMACEUTICALS INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118141-A2 | USE OF CANNABINOID MODULATING COMPOUNDS IN COMBINATION WITH OTHER THERAPEUTIC COMPOUNDS FOR ADJUNCTIVE THERAPY | ACADIA PHARMACEUTICALS INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| EP-1937677-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | Arcadia Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | ACADIA PHARMACEUTICALS | 2007-05-10 | — | — | US | disclosed |
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | ACADIA PHARMACEUTICALS | 2007-05-10 | — | — | US | disclosed |
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| WO-2007047737-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047737-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047776-A1 | IRON CATALYZED CROSS-COUPLING REACTIONS OF IMIDOYL DERIVATIVES | ACADIA PHARMACEUTICALS INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | SDHB, TFRC, SLC40A1 | PLEC 3692/4885CNR1 4354/4885CNR2 4267/4885 |
| US-20070105819-A1 | CB-1 modulating compounds and their use | CNR1, CNR2, FAAH | PLEC 2850/4885CNR1 1/4885CNR2 2/4885 |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | CNR1, CNR2, FAAH | PLEC 2850/4885CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.